Navigation Links
Alzheimer's Med Seems Ineffective in Those With Down Syndrome
Date:1/10/2012

TUESDAY, Jan. 10 (HealthDay News) -- A drug commonly used to treat patients with Alzheimer's disease does not appear to be effective for people older than 40 years who have Down syndrome and Alzheimer's, according to a new study.

Although previous animal studies of the Alzheimer's drug, memantine, showed promising results in mice with Down syndrome, this new study of people with Down syndrome aged 40 and older revealed the opposite, the researchers reported in the Jan. 9 online edition of The Lancet.

Memantine was given to 88 people with Down syndrome for one year, while another 85 patients received a placebo (the "control" group). Some of the participants had Alzheimer's and some didn't.

The investigators found that the brain function of the people in both groups declined equally.

Serious adverse effects were experienced by 11 percent of the group that took the medication. Meanwhile, 7 percent of the placebo group had similar adverse events. Five people from the medication group died because of these events, compared to four in the control group.

"Memantine is not an effective treatment in this group of patients. We believe that this robust finding will have implications for clinical practice and research strategy in the future. Specifically, therapies that are beneficial for people with Alzheimer's disease are not necessarily effective for the treatment of cognitive impairment or dementia in the context of Down syndrome," the study's author, Clive Ballard, a professor at the Wolfson Centre for Age-Related Diseases at King's College London, said in a journal news release.

Because nearly 40 percent of people with Down syndrome over 60 years of age are diagnosed with dementia, the study authors pointed out that more research is needed to determine the best way to treat dementia in these individuals.

"Further investment is urgently needed to develop treatments that are effective in this important group of people," the study's co-author, Anne Corbett, research manager at Alzheimer's Society (U.K.), stated in the news release.

More information

The U.S. National Institute of Neurological Disorders and Stroke provides more information on Alzheimer's disease.

-- Mary Elizabeth Dallas

SOURCE: The Lancet, news release, Jan. 9, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Surgery Seems Most Effective for Herniated Discs
2. 1st Artificial Windpipe Made With Stem Cells Seems Successful
3. Newer Drug Seems Better at Controlling Lupus Kidney Complication
4. Regular Exercise Seems to Guard Against Migraine
5. Diabetes Education Seems to Help Improve Blood Sugar Control
6. Heart Defect Seems to Pose Low Risk of Aorta Tear
7. Special Talk Therapy Seems to Help Dying Patients
8. Satisfaction With Life Seems Good for the Heart
9. When It Comes to Memory, Practice Seems to Make Perfect
10. Ovulation Seems to Aid Womens Gaydar
11. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Alzheimer's Med Seems Ineffective in Those With Down Syndrome
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: